Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study
Primary Objective:
To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
Secondary Objectives:
The control rate of HbA1c ≤6.5% achievement. The control rate of HbA1c <7.0% in patients achieving their FPG target. The percentage of HbA1c <7% without hypoglycemia. The percentage of patients achieving the FPG target without hypoglycemia. The percentage of patients achieving the FPG target and post prandial glucose (PPG) target (2-hour post breakfast <10 mmol/L).
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Anshan、中国
- Investigational Site Number 156053
-
Beijing、中国
- Investigational Site Number 156006
-
Beijing、中国
- Investigational Site Number 156001
-
Beijing、中国
- Investigational Site Number 156002
-
Changchun、中国、130033
- Investigational Site Number 156013
-
Changchun、中国、130033
- Investigational Site Number 156014
-
Changde、中国、415000
- Investigational Site Number 156022
-
Changsha、中国
- Investigational Site Number 156017
-
Changzhou、中国
- Investigational Site Number 156034
-
Chenzhou、中国
- Investigational Site Number 156023
-
Guangzhou、中国、510515
- Investigational Site Number 156026
-
Haikou、中国、570102
- Investigational Site Number 156029
-
Haikou、中国
- Investigational Site Number 156028
-
Haikou、中国
- Investigational Site Number 156040
-
Hangzhou、中国、310013
- Investigational Site Number 156039
-
Hangzhou、中国
- Investigational Site Number 156038
-
Hangzhou、中国
- Investigational Site Number 156042
-
Hangzhou、中国
- Investigational Site Number 156044
-
Hefei、中国
- Investigational Site Number 156048
-
Hefei、中国
- Investigational Site Number 156050
-
Kunming、中国
- Investigational Site Number 156011
-
Kunming、中国
- Investigational Site Number 156052
-
Lanzhou、中国
- Investigational Site Number 156016
-
Lishui、中国
- Investigational Site Number 156041
-
Nanchang、中国、330006
- Investigational Site Number 156020
-
Nanchang、中国
- Investigational Site Number 156018
-
Nanchang、中国
- Investigational Site Number 156019
-
Nanjing、中国
- Investigational Site Number 156031
-
Nanjing、中国
- Investigational Site Number 156043
-
Nanjing、中国
- Investigational Site Number 156049
-
Shanghai、中国
- Investigational Site Number 156035
-
Shanghai、中国
- Investigational Site Number 156036
-
Shanghai、中国
- Investigational Site Number 156047
-
Shantou、中国
- Investigational Site Number 156027
-
Shenyang、中国
- Investigational Site Number 156015
-
Shijiazhuang、中国
- Investigational Site Number 156054
-
Tangshan、中国、063000
- Investigational Site Number 156007
-
Tianjin、中国、300032
- Investigational Site Number 156010
-
Wuhan、中国、430000
- Investigational Site Number 156055
-
Xuzhou、中国
- Investigational Site Number 156037
-
Yangzhou、中国
- Investigational Site Number 156033
-
Yueyang、中国
- Investigational Site Number 156030
-
Zhenjiang、中国、212001
- Investigational Site Number 156032
-
Zhuzhou、中国、412000
- Investigational Site Number 156025
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria :
- 18 to 65 years old.
- Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months:
If on 1 OAD, provided with the following doses (including but not limited to):
- α-glucosidase inhibitor: 100mg, three times a day (tid);
- metformin: 1.5-2.0 g/day;
- sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose;
- thiazolidinediones: eg. pioglitazone, 30-40 mg/day.
- Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert.
- If on 2-3 OADs, any range of dose is acceptable.
- HbA1c >7%, and ≤10.5%.
- FPG >7 mmol/L.
- Body mass index (BMI) ≥20 kg/m^2, and ≤40 kg/m^2.
- Diabetes duration ≥1 year.
- Physician decides to and the patient is willing to start basal insulin (BI) treatment.
- Willing to join the study and sign the informed consent.
Exclusion criteria:
- Type 1 diabetes patients.
- Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months).
- Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening.
- Known hypoglycemia unawareness or recurrent hypoglycemia.
- Hypersensitivity to study drug or its excipients.
- Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up.
- Pregnancy or breastfeeding women.
- Have any mental disorders, lack self-control or not able to express accurately.
- Involved in another clinical trial simultaneously or within a 1 month before start of trial.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Group 1
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
其他名称:
|
实验性的:Group 2
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
其他名称:
|
实验性的:Group 3
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Percentage of patients with HbA1c <7% achievement
大体时间:24 weeks
|
24 weeks
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Percentage of patients achieving HbA1c <=6.5%
大体时间:24 weeks
|
24 weeks
|
Percentage of patients achieving FPG target with HbA1c <7%
大体时间:24 weeks
|
24 weeks
|
Percentage of patients achieving HbA1c <7% without hypoglycemia
大体时间:24 weeks
|
24 weeks
|
Percentage of patients achieving the FPG target without hypoglycemia
大体时间:24 weeks
|
24 weeks
|
Percentage of patients achieving FPG target
大体时间:24 weeks
|
24 weeks
|
Percentage of patients achieving PPG target (2-hour post-breakfast <10 mmol/L)
大体时间:24 weeks
|
24 weeks
|
Change from baseline in HbA1c
大体时间:Baseline to 24 weeks
|
Baseline to 24 weeks
|
Change in FPG
大体时间:8 weeks to 24 weeks
|
8 weeks to 24 weeks
|
Change in PPG
大体时间:Baseline to 24 weeks
|
Baseline to 24 weeks
|
Change in insulin doses in each arm
大体时间:1 week to 24 weeks
|
1 week to 24 weeks
|
Change in body weight in each treatment arm
大体时间:Baseline to 24 weeks
|
Baseline to 24 weeks
|
Percentage of patients experienced hypoglycemic events
大体时间:24 weeks
|
24 weeks
|
合作者和调查者
赞助
出版物和有用的链接
一般刊物
- Wang X, Wu G, Shen D, Zhang X, Yang W. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study. Adv Ther. 2022 Jun;39(6):2820-2830. doi: 10.1007/s12325-022-02128-y. Epub 2022 Apr 16.
- Li L, Yang T, Xue Y, Ruan P, Du J, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III). Adv Ther. 2022 Jan;39(1):421-429. doi: 10.1007/s12325-021-01932-2. Epub 2021 Nov 10.
- Ma J, Lei M, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis. Adv Ther. 2020 Sep;37(9):3816-3826. doi: 10.1007/s12325-020-01410-1. Epub 2020 Jul 15.
- Yang W, Yang Z, Zhao J, Lu H, Luo T. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. Trials. 2016 Sep 26;17(1):470. doi: 10.1186/s13063-016-1588-6.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- LANTUL07190
- U1111-1172-1058 (其他标识符:UTN)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
INSULIN GLARGINE的临床试验
-
Julphar Gulf Pharmaceutical IndustriesParexel; Profil Institut für Stoffwechselforschung GmbH完全的
-
Mannkind Corporation完全的
-
Julphar Gulf Pharmaceutical IndustriesProfil Institut für Stoffwechselforschung GmbH完全的